For ovarian cancer, current biomarkers like carbohydrate antigen 125 (CA125) and human epididymis protein 4 (HE4) suffer from low specificity and sensitivity, leading to high false-positive rates [7]. This evidence concerns the gene WFDC2 and ovarian cancer.